Nahid Salehi

Nahid Salehi


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2014 in Journal of Photochemistry and Photobiology B: Biology
Verified
Journal Article
Closed access
NSNahid Salehi
Nahid Salehi
Ali Akbar Moosavi-MovahediAli Akbar Moosavi-Movahedi
Ali Akbar Moosavi-Movahedi
LFL. Fotouhi
L. Fotouhi
SYSaeed Yousefinejad
Saeed Yousefinejad
MSM. Shourian
M. Shourian
MHM. Habibi-Rezaei
M. Habibi-Rezaei

1 February 2015 in Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy
Verified
Journal Article
Closed access
LFL. Fotouhi
L. Fotouhi
SYSaeed Yousefinejad
Saeed Yousefinejad
NSNahid Salehi
Nahid Salehi
ASA.A. Saboury
A.A. Saboury
NSN. Sheibani
N. Sheibani
Ali Akbar Moosavi-MovahediAli Akbar Moosavi-Movahedi
Ali Akbar Moosavi-Movahedi


17 July 2025 in Lipids in Health and Disease
Verified
Journal Article
Open access
PDF file
ESElham Sharifi-Zahabi
Elham Sharifi-Zahabi
NNNooshin Nasiri
Nooshin Nasiri
FHFatemeh Hajizadeh-Sharafabad
Fatemeh Hajizadeh-Sharafabad
SMSobhan Mohammadi
Sobhan Mohammadi
SSShaghayegh Shahbazi
Shaghayegh Shahbazi
NSNahid Salehi
Nahid Salehi
Increasing data indicate that the concentration of high-density lipoprotein particles (HDL-p) may be a strong indicator of cardiovascular disease. This study aimed to carry out a meta-analysis to examine the link between subclasses of HDL-p and the hazard of mortality in individuals suffering from cardiovascular diseases (CVDs). A rigorous systematic search was executed through Scopus, PubMed, and Web of Science up to April 2025. Seven unique cohort studies were deemed eligible for incorporation in this meta-analysis. The overall hazard was derived by applying a random effects model. The results indicated a negative association of total HDL-p (RR: 0.74, 95% CI: 0.69–0.78, P < 0.001) and small HDL-p with all-cause mortality (RR: 0.69, 95% CI: 0.63–0.75, P < 0.001) for each 5 µmol/l increment. Similarly, each 5 µmol/l large HDL-p was directly related to all-cause mortality (RR: 1.71, 95% CI: 1.14– 2.56; P = 0.009). Moreover, each 5 µmol/l increase in small HDL-p was linked to a 33% reduction in CVD mortality (RR: 0.67, 95% CI: 0.50–0.91; P = 0.01). This study revealed that small and total HDL-p were negatively correlated with all-cause mortality, whereas latge HDL-p was positively related to mortality from all causes. Additionally, small HDL-p had an inverse relationship with CVD mortality in patients with CVD.

5 May 2023 in Health Science Reports
Verified
Journal Article
Open access
PJParisa Janjani
Parisa Janjani
SMSayeh Motevaseli
Sayeh Motevaseli
YSYahya Salimi
Yahya Salimi
SBSousan Mahmoudi Bavandpouri
Sousan Mahmoudi Bavandpouri
AZArash Ziapoor
Arash Ziapoor
SKSahar Karami
Sahar Karami
Background and Aims: Low‐ and middle‐income nations account for at least three‐quarters of cardiovascular disease deaths worldwide. This study aimed to obtain real knowledge about ST segment elevation myocardial infarction (STEMI) patients and provide the context for developing a principles for care quality improvement.Method: This cross‐sectional study was conducted from July 2018 through December 2019. The study sample consisted of1169 eligible patients based on inclusion criteria. The data were collected using the standard EROP and three specialized, trained questionnaires. The collected data were checked by the quality control officer and analyzed using Stata Version 14.Results: Patient baseline characteristics showed that body mass index, low‐density lipoprotein, high‐density lipoprotein, total cholesterol, and triglyceride levels were higher in women. Also, females recorded a considerable history of diabetes mellitus, hypertension, and hypercholesterolemia compared to men. The results also showed that most men were smokers (46.80%). Aspirin (94.27%), statins (91.48%), and clopidogrel (90.68%) were the common medications used at hospital discharge for patients.Conclusion: The present study suggests that identifying and managing modifiable risk factors can improve cardiovascular disease outcomes. Also, considering the early identification of STEMI patients with new therapies can effectively decrease the rate of cardiovascular disease and its attributed health outcomes.

1 November 2021 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
NSNahid Salehi
Nahid Salehi
SMSayeh Motevaseli
Sayeh Motevaseli
PJParisa Janjani
Parisa Janjani
MBMostafa Bahremand
Mostafa Bahremand
RMReza Heidari Moghadam
Reza Heidari Moghadam
MNMahdi Nalini
Mahdi Nalini
Background: Considerable variability in survival rate after ST-segment elevation myocardial infarction (STEMI) is present and outcomes remain suboptimal, especially in low- and middle-income contraries. This study aimed to investigate predictors of 30- day mortality after STEMI, including reperfusion therapy, in a tertiary hospital in western Iran. Methods: In this registry-based cohort study (2016–2019), we investigated reperfusion therapies – primary percutaneous coronary intervention (PPCI), pharmaco-invasive (thrombolysis followed by angiography/percutaneous coronary intervention), and thrombolysis alone – used in Imam-Ali hospital, the only hospital with a PPCI capability in the Kermanshah Province. We estimated hazard ratios (HRs) and 95% confidence intervals (CIs), using Cox proportional-hazard models, to investigate the potential predictors of 30-day mortality including reperfusion therapy, admission types (direct admission/referral from non-PPCI-capable hospitals), demographic variables, coronary risk factors, vital signs on admission, medical history, and laboratory tests. Results: Data of 2428 STEMI patients (mean age: 60.73; 22.9% female) were available. Reperfusion therapy was performed in 84% of patients (58% PPCI, 10% pharmaco-invasive, 16% thrombolysis alone). Only 17% of the referred patients had received thrombolysis at non-PPCI-capable hospitals. Among patients with thrombolysis, only 38.2% underwent coronary angiography/ percutaneous coronary intervention. The independent predictors of mortality were: no reperfusion therapy (HR: 2.01, 95% CI: 1.36–2.97), referral from non-PPCI-capable hospitals (1.73, 1.22–2.46), age (1.03, 1.01–1.04), glomerular filtration rate (0.97, 0.96–0.97), heart rate>100 bpm (1.94, 1.22–3.08), and systolic blood pressure<100 mm Hg (4.92, 3.43–7.04). Mortality was lower with the pharmaco-invasive approach, although statistically non-significant, than other reperfusion therapies. Conclusion: Reperfusion therapy, admission types, age, glomerular filtration rate, heart rate, and blood pressure were independently associated with 30-day mortality. Using a comprehensive STEMI network to increase reperfusion therapy, especially pharmaco-invasive therapy, is recommended.